Indirect comparison favors P2Y12 monotherapy after shortened dual antiplatelet treatment
A trial synthesis favored this single-drug strategy over aspirin for a combined clinical endpoint, but preceding treatment duration complicated the bleeding comparison.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The indirect comparison favored P2Y12 inhibitor monotherapy for a combined endpoint of ischemic and bleeding events after shortened dual therapy. Any bleeding was also lower, although accounting for differences in preceding treatment duration weakened that finding. The combined endpoint remained favorable, but the abstract does not provide absolute event rates.
This abstract-based explanation relies on an indirect comparison between monotherapies. Trials differed in preceding dual-therapy duration and used their own composite endpoint definitions. A common follow-up length and absolute event rates are not reported.
What the combined endpoint means
Net adverse clinical events combined ischemic and bleeding events using each trial’s definition. A favorable result for this composite does not specify how much each component contributed or how many fewer people experienced an event.
Timing affected the interpretation
Accounting for the duration of prior dual therapy reduced differences in bleeding endpoints, but not the composite endpoint. This sensitivity analysis makes treatment timing relevant to interpreting the apparent differences between subsequent single-drug strategies.
The original publication
Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes.
Laudani C, Giacoppo D, Occhipinti G et al.
JACC Cardiovasc Interv · 2025
- PubMed ID
- 40803759
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.